Eli Lilly and Company
COMBINATIONS OF EGFR INHIBITORS AND ANTI-HUMAN VEGFR-2 ANTIBODIES
Last updated:
Abstract:
The present invention relates to a combination of anti-human VEGFR-2 antibodies and human EGFR tyrosine kinase inhibitors for the treatment of T790M-positive EGFR-mutant non-small cell lung cancer.
Status:
Application
Type:
Utility
Filling date:
20 Aug 2018
Issue date:
21 May 2020